Subcutaneous Immunoglobulin Market Trends

Statistics for the 2023 & 2024 Subcutaneous Immunoglobulin market trends, created by Mordor Intelligence™ Industry Reports. Subcutaneous Immunoglobulin trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Trends of Subcutaneous Immunoglobulin Industry

Secondary Immunodeficiency Diseases are Expected to Witness a Strong Growth Over the Forecast Period

AIDS, cancers of the immune system, like leukemia. and immune-complex diseases, like viral hepatitis, are some of the most common examples of secondary immunodeficiency diseases. With the growing burden of the above-mentioned diseases, the segment is believed to witness strong growth in the coming years.

According to the data updated by WHO in July 2022, it was observed that there were around 38.4 million people across the globe living with AIDS in the year 2021. Furthermore, there were approximately 1.5 million new AIDS cases were identified globally in 2021. Among the infected people, 1.7 million were children which is creating a significant burden on the global healthcare industry. Hence, with the high prevalence of secondary immunodeficiency diseases such as AIDS, the segment is expected to grow significantly over the forecast period.

Furthermore, the increasing approvals of drug candidates for secondary immunodeficiency are boosting segment growth. For instance, in January 2022, Octapharma announced that the indication for cutaquig, a human immunoglobulin for subcutaneous administration, was expanded in the European Union (EU), providing more flexible treatment options to a far wider range of patients with secondary immunodeficiency.

The new Global Health Sector Strategies (GHSS) on HIV, viral hepatitis, and sexually transmitted infections, 2022-2030, are seen as an opportunity to refocus global efforts, speed up the response, and recommit to the elimination of viral hepatitis by 2030, according to participants in the third World Hepatitis Summit. Hence, with the increasing focus of various countries on eliminating such diseases, it is expected that there will be a growing demand for immunoglobulin which is believed to propel the segment growth over the forecast period.

Subcutaneous Immunoglobulin Market: Number of People Living With AIDS, (in Million), by Gender, Global, 2021

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall subcutaneous immunoglobulin market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, the high prevalence of immunodeficiency disease patients, the increasing geriatric population in the region, and the established healthcare infrastructure.

As per the data from the American Cancer Society Report 2022, there were an estimated 1.9 million new cancer cases in the United States for the year 2022. Among those, breast cancer, and cancers of the genitals were expected to witness the highest numbers. The report further stated that the burden of cancer in the United States is increasing rapidly which is providing opportunities to the healthcare companies operating in the therapeutics business. Hence, with the high burden of cancer in the United States, the market for subcutaneous immunoglobulin is expected to witness strong growth in the coming years.

Additionally, Canada is also facing a huge burden of cancer in recent years. As per the data from the Government of Canada published in November 2021, it was projected that the number of people living with cancer would reach 229,200 in the year 2021. By accounting for 46% of all diagnoses in 2021, lung, breast, colorectal, and prostate cancers were anticipated to continue being the most frequently diagnosed cancers.

Several key developments are occuring in the United States which is fueling the market growth. For instance, in January 2023, KORU Medical Systems, Inc., one of the leading medical technology companies operating in the drug delivery systems business, announced a development agreement with a pharmaceutical manufacturer of subcutaneous immunoglobulin therapy (SCIg) to develop and seek regulatory approval of the Freedom Infusion System with a SCIg prefilled syringe.

Therefore, looking at the above-mentioned statistics, it is indicated that with the rising burden of cancers in North American countries, there will be growing demand for immunoglobulin which is expected to boost the market growth in coming years.

Subcutaneous Immunoglobulin Market - Growth Rate by Region

Subcutaneous Immunoglobulin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)